Intravenous immunoglobulin in the treatment of sporadic inclusion body myositis: time for new evidence?

Clin Exp Rheumatol. 2024 Feb;42(2):462-463. doi: 10.55563/clinexprheumatol/7x5o3q. Epub 2024 Feb 19.

Authors

Lorenzo Fontanelli¹, Gabriele Vadi², Erika Schirinzi², Giulia Di Rauso³, Gabriele Bellini², Giulia Ricci², Gabriele Siciliano²

Affiliations

¹ Health Science Interdisciplinary Centre, Sant'Anna School of Advanced Studies, Pisa, and Neurology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy. lorenzo.fontanelli@santannapisa.it.
² Neurology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
³ Neurology Unit, Neuromotor & Rehabilitation Department, Azienda USL-IRCCS di Reggio Emilia, Italy.

PMID: 38372729
DOI: 10.55563/clinexprheumatol/7x5o3q

No abstract available

Publication types

Letter

MeSH terms

Humans
Immunoglobulins, Intravenous / therapeutic use
Myositis* / therapy
Myositis, Inclusion Body* / diagnosis
Myositis, Inclusion Body* / drug therapy

Substances

Immunoglobulins, Intravenous